CD276 and neoplasm: Although the efficacy of monotherapies was somewhat satisfactory, the amalgamation of circMVP silencing with ICB resulted in a notable decrease in tumor burden, whereas the combination of circMVP+anti-B7-H3 remarkably ameliorated the overall survival rate (Fig. 7D).